NCT03796026View on ClinicalTrials.gov

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

June 7, 2019

Study Completion Date

June 14, 2019

Conditions
Sleep Apnea, Obstructive
Interventions
DRUG

Seltorexant 40 mg

Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

DRUG

Placebo

Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

Trial Locations (4)

10019

Clinilabs, New York

30342

NeuroTrials Research, Inc., Atlanta

37923

AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville

45212

CTI Clinical Trial and Consulting Services, Cincinnati

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03796026 - A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter